Introduction. Chronic kidney disease (CKD) constitutes a chronic inflammatory state associated with an increase in inflammatory mediators and profibrotic molecules such as tumor necrosis factor-α (TNF-α). Etanercept (ETA) is a TNF inhibitor widely used in treatment of autoimmune inflammatory diseases. However, the effects of TNF-α inhibition in the establishment of CKD have not been fully elucidated. We evaluate the effects of TNF inhibition by ETA in adenine- (Ad-) induced CKD in rats. Methods. Rats were divided into three groups: control, renal injury model, and model plus ETA (2 mg/kg, 3 times per week; sc). Renal injury was induced by Ad administration (100 mg/kg, daily for 2 or 4 w; orogastric). Serum TNF-α levels and biochemical parameters for renal function were evaluated. Histopathological changes in the kidney were assessed using H&E and Masson’s trichrome staining and also immunostaining for tubular cells. Results. Ad administration produced a renal functional decline, tubular atrophy, interstitial inflammation, and fibrosis for 2 w, followed by renal anemia, several renal dysfunctions, tubular atrophy, and fibrosis at 4 w. A significant increase in serum TNF-α levels was observed from 2 w of Ad administration and remained elevated up to 4 w. Treatment with ETA partially reduced kidney damage but was very effective to blocking serum TNF-α. Conclusion. Although inhibition of TNF by ETA was very effective in reducing serum TNF-α, this strategy was partially effective in preventing Ad-induced CKD.
TNF-α is an inflammatory cytokine produced mainly by immune cells such as macrophages/monocyes, and its biological activity depends on binding to its receptors [4]. There are two distinct receptors for TNF (TNFRs): a 55-kilodalton protein (p55) and a 75-kilodalton protein (p75), and the role of both TNF-α and TNFRs in renal dysfunction has been described previously [5, 6].

TNF inhibitors (TNFi) are used clinically to counterbalance the high TNF levels in several autoimmune rheumatic diseases such as rheumatoid arthritis (RA) [7, 8]. Interestingly, treatment of RA with TNFi has been associated with lower risk on incident CKD [9, 10].

Etanercept (ETA) is one of the registered TNFi (Drug-Bank accession DB00005). It is a fusion protein that is composed of the extracellular ligand-binding portion of human p75 TNFR linked to the Fc portion of human IgG1 and acts as a "TNF decoy receptor" by inhibiting the binding of soluble TNF-α to its cell surface receptor [11]. Some studies have reported the effectiveness of ETA-reducing inflammation in different pathologies related with an exacerbated immune response or fibrosis [12–14]. However, the impact of TNF-α inhibition on CKD progression is not fully elucidated.

The chronic adenine (Ad) diet model results in renal dysfunction. Ad is metabolized to 2,8-dihydroxy-adenine which forms crystalline casts within the renal tubules. This induces progressive kidney damage characterized by tubular atrophy accompanied by chronic interstitial inflammation and fibrosis [15–17].

In this study, we employed the adenine-induced chronic kidney disease (Ad-CKD) model to produce rapid-onset kidney damage in rats to assess the effects of ETA on TNF inhibition and its impact on progressive kidney failure.

2. Materials and Methods

2.1. Animals and Treatment. Thirty male Wistar rats weighing approximately 200 g were purchased from Biotério Morelos. Rats were maintained under SPF conditions with a room temperature of 22–26°C and humidity of 50–60% under a 12 h light/dark cycle, with access to standard food and water ad libitum. Animal procedures were approved by the Institutional Animal Care and Use Committee (CIA-TEJ) protocol number 2019-009A.

Rats were randomly divided into three groups (n = 10 per group): control, kidney damage (Ad), and kidney damage plus etanercept (Ad+ETA). The control group received orogastric administration of water and a subcutaneous (sc) injection of normal saline, both vehicles of Ad and ETA, respectively. Kidney damage was carried out by orogastric administration of Ad (Sigma, A8626) at a dose of 100 mg/kg daily for 4 weeks, with a cut-off preliminary at 2 weeks [15, 16]. Etanercept (Enbrel® 50 mg) was administrated by sc injection at a dose of 2 mg/kg, 3 times per week one hour before the dose of Ad. This dose was selected as an average of previous studies reporting antifibrotic effects of ETA [12–14].

2.2. Analysis of Hematological and Biochemical Parameters. Hematic biometry encompasses erythrocyte count, hemoglobin, and hematocrit levels determined by the impedance method. Biochemical tests were carried out to count the levels of serum creatinine (sCr), urine creatinine (UCr), serum urea (sUr), and blood uremic nitrogen (BUN) by means of dry chemistry, in order to evaluate the renal function. Glomerular filtration rate (GFR) was determined using the levels of sCr, UCr, urinary flow, and average kidney weight, using the formula: \([\frac{(uVol \times ml/min) \times UCr}{sCr}] / \) average kidney weight (g) [18].

2.3. Histopathological Analysis. Kidney samples were fixed in 4% paraformaldehyde; one part was dehydrated and embedded in paraffin. Tissues were sectioned (5 μm) with a microscope and then stained with hematoxylin and eosin (H&E) or Masson’s trichrome following standard protocols. Determination of inflammatory infiltrate, tubular damage, and fibrosis was performed by a double-blind semiquantitative analysis. We observed 23 slides, with 2 tissues in each one and 15 fields at 10x and 40x approach for each one. Then, we assessed a score of percentage of damage, inflammation, and fibrosis. The scale considered 0-4 scores or levels according to percentage, where 0 represents the absence or no damage, 1 represents the little presence or minor damage (<25%), 2 represents the presence or damage in approximately the middle of the field (25-50%), 3 represents the presence or damage in approximately two-thirds of field (50-75%), and 4 represents the presence or damage in the entire field (>75%) [19, 20].

Another section of the fixed kidneys was cryoprotected (30% sucrose in PBS, pH7.4) overnight at 4°C and then was embedded in Tissue-Tek (O.C.T. Compound Sakura) and snap frozen at -25°C. Frozen tissues were sectioned (10 μm) with a cryostat for immunofluorescence. Tissues were stained with antibody for Thy-1 (CDw90) (Santa Cruz Biotechnology, sc-6071) at a dilution of 1:250 overnight at 4°C, washed, and then incubated with a secondary antibody, Alexa Fluor® 488 (Invitrogen, A32814). Nuclei were counterstained with DAPI (Invitrogen, 62248). Images were obtained with confocal microscopy (Leica TCS SPE DM5500, software LAS X) at a 40x magnification; 3 cortical fields were analyzed per sample.

2.4. Determination of TNF-α Concentration in Serum. Serum levels of TNF-α were quantified by a commercial ELISA kit, according to the supplier’s instructions (Sigma, RAB0479). Results were analyzed by linear regression adjustment, using the standard concentrations of TNF-α and the absorbance given at 450 nm.

2.5. Statistical Analysis. Statistical analysis was performed using GraphPad Prism version 5 (San Diego, CA, USA). One-way ANOVA was used followed by Dunn’s multiple comparison posttest. The statistically significant differences of the results with a P value ≤ 0.05 were considered. Results are represented as the mean ± standard error (SEM).

3. Results

3.1. Treatment with ETA Reduces Serum Levels of TNF-α in Rats with Kidney Damage. To demonstrate the TNF
inhibition by ETA, we performed an ELISA assay to quantify the levels of TNF-α in serum. Ad administration significantly increased serum TNF-α levels from the second week (570 pg/ml), and they remained high until the fourth week of Ad administration (587 pg/ml) compared to the control (104 pg/ml). Treatment with ETA (Ad+ETA) significantly decreased TNF-α concentrations from week 2 (137 pg/ml) to week 4 (125 pg/ml), compared to the Ad groups without treatment shown in Figure 1.

3.2. Partial Recovery of Kidney Function in Rats with ETA Treatment. First, the kidney appearance was observed. As shown in Figure 2(a), the kidney of the Ad groups differed markedly for the control. Macroscopic changes in the kidney were observed since the second week and persist until fourth week. The kidneys were grossly enlarged, and color change was yellowish with small surface nodules. It is important to note that this enlargement of the kidneys occurred despite the fact that all the animals with Ad administration significantly decreased their weight gain versus the control, although the Ad+ETA group gained more weight compared to the untreated Ad group at both 2 and 4 weeks (Figure 2(b)). In the model group, Ad-CKD (Ad 4 w) kidney is reaching a significant enlargement with a weight of 4.2 g and a length of 2.9 cm versus the control (1.1 g and 1.7 cm). A recovery in weight and size was observed in the Ad+ETA group at fourth week (3.3 g and 2.4 cm, respectively) versus the Ad group (Figures 2(c) and 2(d)).

Next, hematological and biochemical analyses were performed to evaluate renal anemia and kidney function. Chronic kidney damage depletes the number of EPO-producing cells in the kidney; therefore, hemoglobin, hematocrit, and erythrocyte indexes descend. Ad significantly decreased hematic parameters at 4 weeks; however, treatment with ETA did not have an impact on these (Table 1). Moreover, serum creatinine (2.9 ± 0.34 mg/dl), serum urea (276.3 ± 25.1 mg/dl), blood urea nitrogen (BUN) (129.2 ± 11.7 mg/dl) levels, and urinary volume 24 h (41.3 ± 4.7 ml) were significantly increased in animals with Ad, compared to the control group (0.32 ± 0.02 mg/dl, 33.8 ± 1.6 mg/dl, 15.9 ± 0.75 mg/dl, and 11 ± 5.7 ml, respectively) (Figures 3(a), 3(b), 3(c), and 3(e)), while urinary creatinine (68.1 mg/dl) and GFR (0.02 ml/min/g kidney) were significantly decreased in animals with Ad, compared to the control group (119.1 ± 11.3 mg/dl, 0.266 ± 0.03 ml/min/g kidney) (Figure 3(d), Table 1). Interestingly, some of these parameters were improved with ETA treatment. Serum creatinine (2.2 ± 0.26 mg/dl), serum urea (209.6 ± 25.9 mg/dl), and BUN (97.9 ± 12.1 mg/dl) levels were significantly decreased in the Ad+ETA group compared to the Ad group at 4 weeks (Figures 3(a), 3(b), and 3(c)), although there were no differences between the Ad and Ad+ETA groups in urinary creatinine, urinary volume, or GFR (Figures 3(d) and 3(e), Table 1).

Treatment with ETA partially reduces kidney damage prior to the establishment of CKD. Adenine administration produces a persistent inflammation and a progressive scarring evolution to CKD. We found a large accumulation of inflammatory infiltrate in kidney tissue from the second week with a score 3 (62%) and reaching to score 4 (79%) at the fourth week in groups with Ad. The administration of ETA partially decreased the percentage of inflammatory infiltrate by approximately 10% at second week (54%) but only in 3% at 4 weeks (76%), shown in Figure 4(a). Similarly, it was observed that the administration of Ad generated alterations in the renal tubular structure, such as tubular atrophy with interstice expansion and loss and flattening of tubular epithelial cells in the second week with a score 2 (50%) and reaching to score 3 (74%) at four weeks. Treatment with ETA decreased tubular damage by 10% at week 2 with a score 2 (40%) and 17% at week 4 with score 3 (57%) compared to the group without treatment, shown in Figure 3(a). Additionally, in the immunostaining for tubules, we observed a loss of Thy-1 labeling in the groups with Ad compared to the control from two weeks, this loss of labeling being more evident at four weeks, although it seems that treatment with ETA maintains the expression of Thy-1 in the proximal tubules at four weeks (Figure 4(b)). Moreover, the administration of Ad caused peritubular fibrosis from the second week with score 3 (57%) and reaching to score 4 (80%) at the fourth week. Treatment with ETA reduced the percentage of fibrosis by 18% in the second week (39%), but not at four weeks, when the CKD model is already established; both groups showed similar percentage of fibrosis (score 4, 80%) (Figure 4(c)).

4. Discussion

TNF-α is a potent proinflammatory cytokine and important mediator of inflammatory tissue damage. High serum levels of TNF-α are positively correlated with the severity of kidney injury [2]. In our study, the administration of Ad increased the serum levels of TNF-α concentration up to four times from week 2 and remained elevated until week 4, confirming the elevation of this cytokine in the Ad-CKD model. Similar
data has been previously reported, where elevated levels of this cytokine were approximately 3 times more in the Ad group compared to the control [24]. Treatment with ETA significantly reduces circulating levels of TNF-α from the second week up to the fourth week. With these data, we demonstrated an efficient TNF-α inhibition by ETA. This finding is consistent with the action mechanism of ETA that inhibits binding of TNF to cell surface TNFRs, rendering biologically inactive TNF.

Moreover, in our study, we found a progressive deterioration of kidney function induced by Ad. According to previous studies [20, 21], renal anemia and reduced GFR occurred at 4 weeks after Ad administration. Interestingly, partial recovery of kidney function was observed in rats with

Table 1: Hematological parameters and glomerular filtration rate.

| Parameter                                | Control      | Ad 2w | Ad+ETA 2w | Ad 4w | Ad+ETA 4w |
|------------------------------------------|--------------|-------|------------|-------|-----------|
| Erythrocytes (10^6/ml)                   | 7.7 ± 0.1    | 7.6 ± 0.3 | 7.60 ± 0.2 | 6.9 ± 0.0* | 6.9 ± 0.1* |
| Hemoglobin (g/dl)                        | 14.4 ± 0.3   | 14.1 ± 0.6 | 14.01 ± 0.4 | 13.2 ± 0.1* | 13.1 ± 0.3* |
| Hematocrit (%)                           | 42.1 ± 0.9   | 40.1 ± 1.7 | 40.2 ± 1.3 | 38.4 ± 0.3* | 38.2 ± 0.8* |
| Glomerular filtration rate (GFR) (ml/min/g kidney) | 0.266 ± 0.03 | 0.13 ± 0.02* | 0.23 ± 0.09 | 0.02 ± 0.01* | 0.04 ± 0.01* |

Values are represented as the means ± SEM. *P < 0.05. Ad: adenine; ETA: etanercept.

Figure 2: Kidney morphology and weight gain. (a) Photographs representative of the kidneys at 2 and 4 weeks. Image shows altered color, texture, and a progressive enlargement of the kidneys in groups with Ad. ETA treatment improves the appearance of the kidneys. (b) All animals with Ad administration lose body weight, but animals treated with ETA lose less body weight. (c, d) Kidney reaching a significant enlargement in animals with Ad. ETA treatment reduces the increase in kidney weight and size. Values are represented as the means ± SEM, *P < 0.05. Ad: adenine; ETA: etanercept.
ETA treatment. Serum creatinine, serum urea, and BUN levels were significantly decreased in the Ad+ETA group at 4 weeks.

In addition, as previously mentioned, it is well known that Ad administration induced renal toxicity associated with tubular injury and produced persistent inflammation and a progressive scarring evolution to CKD [16, 19, 22]. In accordance with this, in our study, we analyzed renal morphology and histology. A large amount of inflammatory infiltrate, tubular atrophy, and interstitial fibrosis was found from the second week of Ad administration and becoming severer at 4 weeks. An immunostaining to Thy-1 (CDw90) confirms the tubular atrophy in proximal tubular cells in the Ad groups and shows a protective role of ETA in kidney parenchyma cells. Overall, morphological observation and pathological staining showed that ETA ameliorated kidney injury in rats. ETA attenuated morphological changes and reduced inflammatory infiltrate, tubular atrophy, or interstitial fibrosis induced by Ad at 2 weeks. However, ETA treatment partially reduced inflammatory infiltrate or tubular atrophy, but was not effective to prevent renal fibrosis induced by Ad at 4 weeks.

Although, some studies showed that treatments with TNF-α inhibitors have shown protective effects in the models of acute kidney injury (AKI) such as ischemia/reperfusion (I/R) injury [23, 24], but there are few evidences about the effects of TNF-α blockers in the models of chronic kidney damage [25, 26]. Recently, a study of an 8-week ETA treatment in mice with aristolochic acid (AA) nephropathy as a model of kidney fibrosis found that ETA partially but
significantly attenuated kidney fibrosis and ameliorated albuminuria without affecting kidney function [14]. As previously mentioned, in our study, although we found an improvement in some renal function parameters and observed less tissue damage, we did not find a significant reduction in renal fibrosis with ETA treatment. This could be because the protective effects of TNF-α blockers could be more effective in the models of acute damage or using higher doses. Besides that, several factors participate in the pathophysiology of CKD: initiation (proinflammatory cytokines such as TNF-α, IL-6, oxidative stress, and TGF-β), transition (TGF-β, CTGF, and NF-κB), and establishment (TGF-β, activation of myofibroblasts, ECM, and collagen types I, II, and IV) where multiple profibrogenic molecules participate [27, 28].

5. Conclusion

Treatment with ETA reduces circulating TNF-α levels and the severity of adenine-induced tubular damage prior to the establishment of the CKD model. However, inhibition of TNF-α is not sufficient to avoid the progression of kidney fibrosis.
damage to fibrosis. Actually, it has been widely reported that establishment of fibrosis is a complex phenomenon that ultimately depends on several proinflammatory/anti-inflammatory balance, as well as tissue remodeling molecules (metalloproteinases, integrins, growth factors, etc.), including many other regulators, involving a highly orchestrated event that determines tissue homeostasis, as well as the initiation of inflammation, reinforcement, and perpetuation. In addition, other factors like time of exposition, concentration, and elimination of the nephotoxic etiological agent compromise the efficiency to carry out the removal of the extracellular matrix. Therefore, although inhibition of TNF by ETA is effective in blocking TNF-α, this strategy was partially effective in preventing Ad-induced CKD.

Data Availability

All data generated or analyzed during this study are included in this article and/or its supplementary material files. Further inquiries can be directed to the corresponding author.

Ethical Approval

This study protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) (CICUAL-CIATEJ), approval number (2019-009A).

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

Conceptualization was supervised by A.L.M.A. Methodology was supervised by E.C.V.T. and E.M.C. Writing the original draft preparation was supervised by E.C.V.T. and F.J.G.G. Writing the review and editing was supervised by O.P.M. and E.M.C. Visualization was supervised by A.C.A. Supervision was headed by I.Y.S. Project administration and funding acquisition were supervised by A.L.M.A. All authors have read and agreed to the published version of the manuscript. Edgar Mendieta-Condado and Elda Cristina Villaseñor-Tapia contributed equally to this work.

Acknowledgments

This research was funded by the Consejo Nacional de Ciencia y Tecnología (CONACYT) (grant number 898594) scholarship.

References

[1] A. C. Webster, E. V. Nagler, R. L. Morton, and P. Masson, “Chronic kidney disease,” Lancet, vol. 389, no. 10075, pp. 1238–1252, 2017.
[2] J. Gupta, N. Mitra, P. A. Kanetsky et al., “Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 12, pp. 1938–1946, 2012.
[3] W. Lv, G. W. Booza, Y. Wang, F. Fan, and R. J. Roman, “Inflammation and renal fibrosis: recent developments on key signaling molecules as potential therapeutic targets,” European Journal of Pharmacology, vol. 820, pp. 65–76, 2018.
[4] H. T. Idriss and J. H. Naismith, “TNF alpha and the TNF receptor superfamily: structure-function relationship(s),” Microscopy Research and Technique, vol. 50, no. 3, pp. 184–195, 2000.
[5] R. S. Al-Lamki and T. N. Mayadas, “TNF receptors: signaling pathways and contribution to renal dysfunction,” Kidney International, vol. 87, no. 2, pp. 281–296, 2015.
[6] G. Guo, J. Morrissey, R. McCracken, T. Tolley, and S. Klahr, “Role of TNFRI and TNFRII receptors in tubulointerstitial fibrosis of obstructive nephropathy,” The American Journal of Physiology, vol. 277, no. 5, pp. F766–F772, 1999.
[7] D. Aletaha and J. S. Smolen, “Diagnosis and management of rheumatoid arthritis,” JAMA, vol. 320, no. 13, pp. 1360–1372, 2018.
[8] F. Conti, F. Ceccarelli, L. Massaro et al., “Biological therapies in rheumatic diseases,” La Clinica Terapeutica, vol. 164, no. 5, pp. e413–e428, 2013.
[9] K. Sumida, M. Z. Molnar, P. K. Potukuchi et al., “Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease,” Kidney International, vol. 93, no. 5, pp. 1207–1216, 2018.
[10] S. K. Cho, Y. K. Sung, S. Park, and S. C. Bae, “Etanercept treatment in rheumatoid arthritis patients with chronic kidney failure on predialysis,” Rheumatology International, vol. 30, no. 11, pp. 1519–1522, 2010.
[11] H. Lim, S. Lee, H. Lee et al., “Structural biology of the TNFα antagonists used in the treatment of rheumatoid arthritis,” International Journal of Molecular Sciences, vol. 19, no. 3, p. 768, 2018.
[12] M. Abdul-Hamid, R. R. Ahmed, N. Moustafa, and R. Nady, “The antifibrogenic effect of etanercept on development of liver cirrhosis induced by thioacetamide in rats,” Ultrasound Pathology, vol. 41, no. 1, pp. 23–35, 2017.
[13] C. C. Hsu, Y. Li, C. T. Hsu et al., “Etanercept ameliorates cardiac fibrosis in rats with diet-induced obesity,” Pharmaceuticals (Basel), vol. 14, no. 4, p. 320, 2021.
[14] S. Taguchi, K. Azushima, T. Yamaji et al., “Effects of tumor necrosis factor-α inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy,” Scientific Reports, vol. 11, no. 1, p. 23587, 2021.
[15] T. Yokozawa, H. Oura, P. D. Zheng, M. Fukase, F. Koizumi, and M. Kanaoka, “Metabolic effects of dietary purine and pyrimidine bases in rats,” Agricultural and Biological Chemistry, vol. 47, no. 6, pp. 1297–1304, 1983.
[16] D. Fong, M. M. Ullah, J. G. Lal et al., “Renal cellular hypoxia in adenine-induced chronic kidney disease,” Clinical and Experimental Pharmacology & Physiology, vol. 43, no. 10, pp. 896–905, 2016.
[17] V. Diwan, L. Brown, and G. C. Gobe, “Adenine-induced chronic kidney disease in rats,” Nephrology (Carlton), vol. 23, no. 1, pp. 5–11, 2018.
[18] G. Krinke, Handbook of Experimental Animals, Academic Press, London, 1st edition, 2000.
[19] V. Diwan, D. Small, K. Kauter, G. C. Gobe, and L. Brown, “Gender differences in adenine-induced chronic kidney disease and cardiovascular complications in rats,” American
[20] E. Vázquez-Méndez, Y. Gutiérrez-Mercado, E. Mendieta-Conrado et al., "Recombinant erythropoietin provides protection against renal fibrosis in adenine-induced chronic kidney disease," *Mediators of Inflammation*, vol. 2020, Article ID 8937657, 11 pages, 2020.

[21] A. Rahman, D. Yamazaki, A. Sufun et al., "A novel approach to adenine-induced chronic kidney disease associated anemia in rodents," *PLoS One*, vol. 13, no. 2, article e0192531, 2018.

[22] V. Diwan, A. Mistry, G. Gobe, and L. Brown, "Adenine-induced chronic kidney and cardiovascular damage in rats," *Journal of Pharmacological and Toxicological Methods*, vol. 68, no. 2, pp. 197–207, 2013.

[23] D. E. Choi, J. Y. Jeong, B. J. Lim, K. R. Na, Y. T. Shin, and K. W. Lee, "Pretreatment with the tumor necrosis factor-α blocker etanercept attenuated ischemia-reperfusion renal injury," *Transplantation Proceedings*, vol. 41, no. 9, pp. 3590–3596, 2009.

[24] C. Tasdemir, S. Tasdemir, N. Vardi et al., "Protective effect of infliximab on ischemia/reperfusion-induced damage in rat kidney," *Renal Failure*, vol. 34, no. 9, pp. 1144–1149, 2012.

[25] N. N. Younis, H. E. Mohamed, M. A. Abdelghafour, and S. K. Hammad, "Inactivation of Wnt/β-catenin/renin angiotensin axis by tumor necrosis factor-alpha inhibitor, infliximab, ameliorates CKD induced in rats," *Biochemical Pharmacology*, vol. 185, article 114426, 2021.

[26] S. B. Khan, H. T. Cook, G. Bhangal, J. Smith, F. W. K. Tam, and C. D. Pusey, "Antibody blockade of TNF-α reduces inflammation and scarring in experimental crescentic glomerulonephritis," *Kidney International*, vol. 67, no. 5, pp. 1812–1820, 2005.

[27] B. D. Humphreys, "Mechanisms of renal fibrosis," *Annual Review of Physiology*, vol. 80, no. 1, pp. 309–326, 2018.

[28] A. Nogueira, M. J. Pires, and P. A. Oliveira, "Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies," *In Vivo*, vol. 31, no. 1, pp. 1–22, 2017.